Systemic Lupus Erythematosus (SLE) Clinical Trial
Official title:
Efficacy, Safety, and Steroid Sparing Effect of Acthar in Patients With Hematologic Manifestations of Systemic Lupus Erythematosus
This is a randomized study exploring the efficacy, safety and steroid sparing ability of two doses (40 U and 80 U) of Acthar in SLE patients with immune mediated hematologic manifestations requiring steroid use for a minimum of 2 weeks prior to screening.
Acthar is currently labeled for use during an exacerbation or for maintenance therapy in selected SLE cases, however data from prospective trials on hematologic manifestations of SLE are not available. Due to the potential effect of lowering or eliminating autoantibodies, the absence of bone marrow suppression, and a steroid sparing effect, Acthar may represent a novel therapeutic option in recalcitrant cases of hematologic SLE. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04461158 -
CCCR Lupus Patient Navigator Program
|
N/A | |
| Completed |
NCT02006784 -
Pilot Study to Assess Flares Following Inactivated Influenza Vaccine in Children With Systemic Lupus Erythematosus (SLE)
|
N/A | |
| Completed |
NCT01072734 -
Auto-immunity in Lupus Patients After Influenza Vaccine
|
Phase 2 | |
| Completed |
NCT03626311 -
Omega-3 Replacement With Krill Oil in Disease Management of SLE
|
N/A | |
| Completed |
NCT01992666 -
GENetic & Immunologic Abnomalies in Systemic Lupus Erythematosus
|
N/A | |
| Completed |
NCT00779194 -
Prospective Study of Rapamycin for the Treatment of SLE
|
Phase 2 | |
| Recruiting |
NCT00582881 -
Characteristics and Disease Progression of Mixed Connective Tissue Disease and Systemic Lupus Erythematosus
|
||
| Terminated |
NCT02811094 -
LUMIER² Study : LUpus Molecular Immunomonitoring to Evaluate the Risk of Relapse
|
N/A | |
| Recruiting |
NCT05458622 -
3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erithematosus Study Protocol
|
Phase 3 | |
| Recruiting |
NCT06144710 -
SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus
|
Phase 1 | |
| Completed |
NCT03031925 -
Detection of Annexin A2 in Systemic Lupus Erythematosus
|
N/A | |
| Not yet recruiting |
NCT06420154 -
The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases
|
Early Phase 1 | |
| Recruiting |
NCT05859997 -
Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases
|
N/A | |
| Recruiting |
NCT02782039 -
Register of Patients With Anti-Phospholipids Syndrome (APS) and/or Systemic Lupus Erythematosus (SLE)
|
||
| Recruiting |
NCT05567198 -
Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires
|
||
| Recruiting |
NCT05747651 -
3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erythematosus Study Protocol 2
|
||
| Recruiting |
NCT03030976 -
A Study of CD19 Redirected Autologous T Cells for CD19 Positive Systemic Lupus Erythematosus (SLE)
|
Phase 1 | |
| Recruiting |
NCT06249438 -
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
|
Phase 1 | |
| Not yet recruiting |
NCT05724940 -
Comparison of Clinical and Serological Differences Among Juvenile, Adult, and Late-onset Systemic Lupus Erythematosus
|
||
| Recruiting |
NCT06032923 -
Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus
|
Phase 1/Phase 2 |